A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
Clinical trial NCT03118713 · TERMINATED
Trial details
- NCT number
- NCT03118713
- Sponsor
- Astellas Pharma Korea, Inc.
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-25
- Primary completion
- 2018-12-12
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.